Cell engineering

MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections

Retrieved on: 
Monday, September 13, 2021
U.S. Securities and Exchange Commission, Security (finance), Investment, Cell engineering, CARMA, Traction, Drug discovery, Cell, CEO, Engineering, SPL, LSE, Prospectus, Projection, IPO, Investor, Conference, Adoption, Company, Instituto de Biologia Molecular e Celular, Private Securities Litigation Reform Act, Nasdaq, Total, ATX, GTX, NASDAQ, Expert, Growth, COVID-19, Interest, GLOBE, Risk, STX, Mobile phone, Video game, Pharmaceutical industry, Film

Total revenue of $7.1 million in the second quarter of 2021, representing 38% growth compared to the same period in 2020

Key Points: 
  • Total revenue of $7.1 million in the second quarter of 2021, representing 38% growth compared to the same period in 2020
    Excluding SPL Program-related revenue, revenue from cell therapy customers was $4.8 million for the second quarter, an increase of 59% year-over-year, while revenue from drug discovery customers was $1.8 million in the second quarter, an increase of 60% year-over-year.
  • Total revenue for the second quarter of 2021 was $7.1 million, compared to $5.2 million in the second quarter of 2020, representing year-over-year growth of 38%.
  • The Company recognized $0.5 million in Program-related revenue in the quarter (comprised of pre-commercial milestone revenues) as compared to $1.0 million in Program-related revenue in the second quarter of 2020.
  • Operating expenses for the second quarter of 2021 were $10.7 million, compared to operating expenses of $7.5 million in the second quarter of 2020.

Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience

Retrieved on: 
Thursday, September 9, 2021

The new mRNA Cleanroom facility is an important part of our planned R&D operations, and of strategic advantage as we share the space with Factor Biosciences, from which we have in-licensed critical mRNA and gene editing technology, said Dr. Federoff.

Key Points: 
  • The new mRNA Cleanroom facility is an important part of our planned R&D operations, and of strategic advantage as we share the space with Factor Biosciences, from which we have in-licensed critical mRNA and gene editing technology, said Dr. Federoff.
  • We are also pleased to wish Factor Bioscience and its co-founders, Drs.
  • The facility was custom designed for Brooklyns needs in cell engineering, with capacity sufficient to support both near- and long-term clinical development.
  • The facility provides Brooklyn with access to 2,700 square feet of contiguous lab space that will support the creation of seven R&D jobs.

MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021

Retrieved on: 
Thursday, September 2, 2021
GLOBE, Company, LSE, Conference, Cell engineering, Biotechnology, NASDAQ, Interest

GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. market close on Monday, September 13th, 2021.

Key Points: 
  • GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. market close on Monday, September 13th, 2021.
  • Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
  • A live and archived webcast of the event will be available on the Events section of the MaxCyte website at https://investors.maxcyte.com/ .
  • MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs.

MaxCyte Signs Clinical and Commercial License with Sana Biotechnology

Retrieved on: 
Monday, August 9, 2021
LSE, Achievement, Nasdaq, Expert, Biotechnology, Efficiency, SANA, CEO, Cell engineering, Company, Pharmaceutical industry, Fine chemical

GAITHERSBURG, Md., Aug. 9, 2021 /PRNewswire/ -- MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines.

Key Points: 
  • GAITHERSBURG, Md., Aug. 9, 2021 /PRNewswire/ -- MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, today announced the signing of a clinical and commercial license with Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines.
  • Under the terms of the agreement, Sana Biotechnology obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPERT platform.
  • In return, MaxCyte is entitled to receive platform licensing fees and program-related milestone payments.
  • MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs.